Abaloparatide

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abaloparatide and local guidelines before prescribing.

Anabolic bone agent

Mechanism

PTHrP analogue (anabolic).

Uses

Severe postmenopausal osteoporosis.

Dosing

Side effects

Dizziness, palpitations, hypercalcaemia, injection-site reactions.

Interactions

Few.

Contraindications and cautions

Hypercalcaemia, Paget disease

Monitoring

Calcium

Pregnancy and breastfeeding

Not for use

Renal and hepatic impairment

Avoid in severe renal impairment

Overdose and reversal

Supportive

Special advice

Maximum 18 months; follow with antiresorptive.

More from the textbook: uses, cautions and other points
Where it is discussed in the book